Biochemical markers of bone turnover

References

• Beardsworth L J., Eyre D R., Dickson I R. Changes with age in the urinary excretion of lysyl-and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J Bone Miner Res 1990; 5: 671–6
   PubMed Web of Science ®Google Scholar
• Black D, Duncan A, Robins S P. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 1988; 169: 197–3
   PubMed Web of Science ®Google Scholar
• Bonde H., Quist P, Fidelins C, Riss B J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994; 40: 2022–5
   PubMed Web of Science ®Google Scholar
• Brown J P., Delmas P D., Arlot M, et al. Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis. J Clin Endocrinol Metab 1987; 64: 954–9
   PubMed Web of Science ®Google Scholar
• Brown J P., Delmas P D., Malaval L, et al. Serum bone Glaprotein: A specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984; i: 1091–3
   Google Scholar
• Charles P, Poser J W., Mosekilde L, Jensen F T. Estimation of bone turnover evaluated by 47 calcium kinetics. Efficiency of serum bone gamma-carboxyglutamic acid containing protein, serum alkaline phosphatase and urinary hydroxyproline excretion. J Clin Invest 1985; 76: 2254–8
   PubMed Web of Science ®Google Scholar
• Crilly R G., Jones M M., Horsman A, et al. Rise in plasma alkaline phosphatase at the menopause. Clin Sci 1980; 53: 341–2
   Google Scholar
• Delmas P D. Biochemical markers of bone turnover in osteoporosis. Osteoporosis: Etiology, Diagnosis and Management, B L. Riggs, L J. Metton. Raven Press, New York 1988; 297
   Google Scholar
• Delmas P D., Stenner D, Wahner H W., et al. Serum bone gla-protein increases with aging in normal women: implications for the mechanism of age-related bone loss. J Clin Invest 1983; 71: 1316–21
   PubMed Web of Science ®Google Scholar
• Delmas P D., Wilson D M., Mann K G., et al. Effect of renal function on plasma levels of bone gla-protein. J Clin Endocrinol Metab 1983; 57: 1028–30
   PubMed Web of Science ®Google Scholar
• Delmas P D. Biochemical markers of bone turnover for the clinical assessment of metabolic disease. Endocrin Metab Clin North America 1990; 19: 11–18
   Google Scholar
• Delmas P D., Demiaux B, Malaval L, et al. Serum bone gla-protein (osteocalcin) in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry. J Clin Invest 1986; 77: 985–91
   PubMed Web of Science ®Google Scholar
• Delmas P D., Christiansen C, Mann K G., Price P A. Bone gla-protein (osteocalcin) assay standardization report. J Bone Miner Res 1990; 1: 5–11
   Google Scholar
• Delmas P D., Schlemmer A, Gineyts E, Riis B, Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991; 6: 639–44
   PubMed Web of Science ®Google Scholar
• Delmas P D., Gineyts E, Bertholin A, Garnero P, Marchand F. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res 1993; 5: 643–8
   Google Scholar
• Duda R J., O'Brien J F., Katzmann J A., et al. Concurrent assays of circulating bone gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab 1988; 66: 951–7
   PubMed Web of Science ®Google Scholar
• Eastell R, Delmas P D., Hodgson S F., et al. Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics and biochemical markers. J Clin Endocrinol Metab 1988; 67: 741–8
   PubMed Web of Science ®Google Scholar
• Eastell R, Hampton L, Colwell A. Urinary collagen crosslinks are highly correlated with radio isotopic measurements of bone resorption. Proceedings of the Third International Symposium on Osteoporosis, C Christiansen, K Overgaard. Osteopress, AalborgDenmark 1990; 469–70
   Google Scholar
• Eastell R, Calvo M S., Burritt M F., Offord K P., Russell R G G, Riggs B L. Anormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J Clin Endocrinol Metab 1992; 74: 487–94
   PubMed Web of Science ®Google Scholar
• Ebeling P R., Peterson J M., Riggs B L. Utility of Type I Procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992; 7: 1243–50
   PubMed Web of Science ®Google Scholar
• Eyre D R. Collagen crosslinking amino-acids. In: Methods in Enzymology 1987; 144: 115–39
   PubMed Web of Science ®Google Scholar
• Eyre D R., Koob T J., van Ness K P. Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Anal Biochem 1984; 137: 380–8
   PubMed Web of Science ®Google Scholar
• Eyre D R., Dickson I R., van Ness K P. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues. Biochem J 1988; 252: 495–500
   PubMed Web of Science ®Google Scholar
• Eyres K S., McCloskey E V., Fern E D., et al. Serum type I collagen carboxyterminal crosslinked telopeptide (S-1 CTP) in Paget's disease of bone and the effect of treatment with bisphosphonates. Bone Miner 1992; 17: S29
   Google Scholar
• Farley J R., Chesnut C J., Baylink D J. Improved method for quantitative determination in serum alkaline phosphatase of skeletal origin. Clin Chem 1981; 27: 2002–7
   PubMed Web of Science ®Google Scholar
• Fujimoto D, Morigachi T, Ishida T, Hayashi H. The structure of pyridinoline, a collagen crosslink. Biochem Biophys Res Comm 1978; 84: 52–7
   PubMed Web of Science ®Google Scholar
• Garnero P, Delmas P D. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993; 77: 41046–53
   Google Scholar
• Garnero P, Grimaux M, Seguin P, Delmas P D. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994; 9(2)255–64
   PubMedGoogle Scholar
• Garnero P, Gineyts E, Riou J P., Delmas P D. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994; 3: 780–5
   Google Scholar
• Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas P D. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound crosslinks excretion. J Bone Miner Res 1995; 10: 641–9
   PubMed Web of Science ®Google Scholar
• Garnero P, Shih W J., Gineyts E, Karpf D B., Delmas P D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693–1700
   PubMed Web of Science ®Google Scholar
• Gundberg C, Weinstein R S. Multiple immunoreactive forms in uremic serum. J Clin Invest 1986; 77: 1762–7
   PubMed Web of Science ®Google Scholar
• Hanson D A., Weiss M AE, Bollen A M., Maslan S L., Singer F R., Eyre D R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992; 7: 1251–8
   PubMed Web of Science ®Google Scholar
• Hansen M A., Kirsten O, Riis B J., Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 years study. Brit Med J 1991; 303: 961–4
   PubMed Web of Science ®Google Scholar
• Hassager C, Fabbri-Mabelli G, Christiansen C. The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type I collagen. Osteoporosis Int 1993; 3: 50–2
   PubMed Web of Science ®Google Scholar
• Hassager C, Jensen L T., Podenphant J, Thomsen K, Christiansen C. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of Nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 1994; 54: 30–3
   PubMed Web of Science ®Google Scholar
• Hill C S., Wolfert R L. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clinica Chimica Acta 1986; 186: 315–20
   Google Scholar
• Johansen J S., Riis B J., Delmas P D., et al. Plasma BGP: an indicator of spontaneous bone loss and effect of estrogen treatment in postmenopausal women. Eur J Clin Invest 1988; 18: 191–195
   PubMed Web of Science ®Google Scholar
• Kivirikko K I. Excretion of urinary hydroxyproline peptide in the assessment of bone collagen deposition and resorption. Clinical Disorders of Bone and Mineral Metabolism, B Frame, J T. Potts, Jr. Excerpta Medica, Amsterdam 1983; 105–7
   Google Scholar
• Krane S M., Kantrowitz F G., Byrne M, Pinnel S R., Singer F R. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. J Clin Invest 1977; 59: 819–27
   PubMed Web of Science ®Google Scholar
• Kraenzlin M, Lau K H W, Liang L. Development of an immunoassay for human serum osteoclastic tartrate resistant acid phosphatase. J Clin Endocrinol Metab 1990; 71: 442–51
   PubMed Web of Science ®Google Scholar
• Li CY, Chuda R A., Lam W K W, et al. Acid phosphatase in human plasma. J Lab Clin Med 1973; 82: 446–60
   PubMedGoogle Scholar
• Lian J B., Gundberg C M. Osteocalcin Biochemical considerations and clinical applications. Clin Orthop 1988; 226: 267–91
   PubMed Web of Science ®Google Scholar
• Lowry M, Hall D E., Brosnan J J. Hydroxyproline metabolism by the rat kidney: Distribution of renal enzymes of hydroxyproline catabolism and renal conversion of hydroxyproline to glycine and serine. Metabolism 1985; 39: 955
   Google Scholar
• Minkin C. Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982; 34: 285–90
   PubMed Web of Science ®Google Scholar
• Moro L., Mucelli R S P, Gazzarrini C, et al. Urinary 6-1-galactosyl-O-hydroxylysine (GH) as a marker of collagen turnover of bone. Calcif Tissue Int 1988; 42: 87–90
   PubMed Web of Science ®Google Scholar
• Moss D W. Alkaline phosphatase isoenzymes. Clin Chem 1982; 28: 2007–16
   PubMed Web of Science ®Google Scholar
• Parfitt A M., Simon L S., Villanueva A R., et al. Procollagen Type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987; 2: 427–36
   PubMed Web of Science ®Google Scholar
• Podenphant J, Johansen J S., Thomsen K, et al. Bone turnover in spinal osteoporosis. J Bone Miner Res 1987; 2: 497–503
   PubMedGoogle Scholar
• Price P A. Vitamin K-dependent bone proteins. Calcium regulation and bone metabolism: basic and clinical aspects, D V. Cohn, T J. Martin, P J. Meunier. Elsevier Science Publishers BV. 1987; 9: 419–26
   Google Scholar
• Price P A., Parfhemore J G., Deftos L J. New biochemical marker for bone metabolism. J Clin Invest 1980; 66: 878–83
   PubMed Web of Science ®Google Scholar
• Price P A., Williamson M K., Lothringer J W. Origin of vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem 1981; 256: 12760–6
   PubMed Web of Science ®Google Scholar
• Prockop O J., Kivirikko K I. Hydroxyproline and the metabolism of collagen. Treatise on Collagen, B S. Gould. Academic Press, New York 1968; 215–16
   Google Scholar
• Prockop O J., Kivirikko K I., Tuderman K, et al. The biosynthesis of collagen ant its disorders. N Engl J Med 1979; 301: 13–23
   PubMed Web of Science ®Google Scholar
• Ristelli J, Elomaa I, Niemi S, Novamo A, Ristelli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635–40
   PubMedGoogle Scholar
• Robins S P., Black D, Paterson C R., Reid D M., Duncan A, Seibel M J. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone disease. Europ J Clin Invest 1991; 21: 310–5
   PubMed Web of Science ®Google Scholar
• Robins S P., Woitge H, Hesley R, Ju J, Seyedin S, Seibel M J. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J. Bone Miner Res 1994; 9: 1643–9
   PubMed Web of Science ®Google Scholar
• Schlemmer A, Hassager C, Jensen S B., Christiansen C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 1992; 74: 476–80
   PubMed Web of Science ®Google Scholar
• Seibel M J., Robins S P., Bilezikiau J P. Urinary pyridinium crosslinks of collagen. Trends Endocrinol Metab 1992; 3: 263–70
   PubMed Web of Science ®Google Scholar
• Seyedin S, Zuk R, Kung V, Daniloff Y, Shepard K. An immunoassay to urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 1993; 8: 635–42
   PubMed Web of Science ®Google Scholar
• Slemenda C, Hui S L., Longcope C, et al. Sex steroids and bone mass. A study of changes about the time of menopause. J Clin Invest 1987; 80: 1261–69
   PubMed Web of Science ®Google Scholar
• Smedsrod B, Melkko J, Ristelli L, Ristelli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 1990; 271: 345–50
   PubMed Web of Science ®Google Scholar
• Stepan J J., Silinkova-Malkova E, Havrenek T, et al. Relationship of plasma tartrate-resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta 1983; 133: 189–200
   PubMed Web of Science ®Google Scholar
• Stepan J J., Pospichal J, Presl J, et al. Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 1987; 8: 279–84
   PubMed Web of Science ®Google Scholar
• Szulc P, Chapuy M C., Meunier P J., Delmas P D. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 1993; 91: 1769–74
   PubMed Web of Science ®Google Scholar
• Taylor A K., Linkart S, Mohan S, Chrinstenson R A., Singer F R., Baylink D. Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay. J Clin Endocrinol Metab 1990; 70: 467–72
   PubMed Web of Science ®Google Scholar
• Thomsen K, Rodbro P, Christiansen C. Bone turnover determined by urinary excretion of [99m TC] disphosphonate in the prediction of postmenopausal bone loss. Bone Miner 1987; 2: 125–31
   PubMedGoogle Scholar
• Tracy R P., Andrianorivo A, Riggs B L., Mann K G. Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin. A study of sources of variation in assay results. J Bone Miner Res 1990; 5: 451–61
   PubMedGoogle Scholar
• Uebelhart D, Schlemmer A, Johansen J, Gineyts E, Christiansen C, Delmas P D. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J Clin Endocrinol Metab 1991; 72: 367–73
   PubMed Web of Science ®Google Scholar
• Uebelhart D, Gineyts E, Chapuy M C., Delmas P D. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990; 8: 87–96
   PubMedGoogle Scholar